Show simple item record

AuthorMarei, Hany E.
AuthorAlthani, Asmaa
AuthorSuhonen, Jaana
AuthorEl Zowalaty, Mohamed E.
AuthorAlbanna, Mohammad A.
AuthorCenciarelli, Carlo
AuthorWang, Tengfei
AuthorCaceci, Thomas
EditorRahman, Atta-ur-
Available date2016-07-24T07:21:30Z
Publication Date2016
Publication NameFrontiers in Clinical Drug Research - Alzheimer Disorders
ISBN978-1-68108-232-5
ISSN1387-2877
URIhttp://hdl.handle.net/10576/4687
URIhttp://dx.doi.org/10.2174/97816810823181160501
AbstractAlzheimer's disease (AD) is a complex neurodegenerative condition that is clinically characterized by impaired cognitive functions. The major morphologically observed lesion of AD encompasses the accumulation of extracellular amyloid aggregates (plaques) formed of amyloid-β (Aβ) protein and of intracellular neurofibrillary tangles (NFT) of hyperphosphorylated Tau protein. According to the currently accepted amyloid cascade hypothesis, the major induction factor underlying the loss of cholinergic neurons in the cortex and hippocampus is the pathological accumulation of a smaller protein fragments known as amyloid-β which in turn is derived from a larger membrane protein called amyloid precursor protein (APP). Based on this hypothesis, several diagnostic and drug-based therapeutic interventions were suggested, mostly targeting amyloid-β and hyperphosphorylated Tau proteins. Several data have emerged that might indicate the inconsistency of the amyloid cascade hypothesis. Moreover, due to the purely palliative nature of AD drugs used so far, new stem cell-based therapy has been suggested as a promising potential therapeutic approach. Several cell sources have been used, such as embryonic stem cells, neural stem cells, mesenchymal stem cells, and induced pluripotent stem cells. While this suite of cell-based trials has shown promising results in preclinical paradigms, stumbling blocks still exist in the current treatment regimens. The present review highlights the recent perspective that argues against the long standing amyloid cascade hypothesis as well as the major efforts in the experimental application of stem cellbased therapies used as treatment options for AD, and discusses the major impediments against their successful translation into clinical.
SponsorBRC, QU
Languageen
PublisherBentham Science
SubjectAβ42 peptides
Alzheimer's disease
Amyloidogenesis
Amyloid beta protein
Amyloid precursor protein (APP)
Stem cells-Therapy
Pathogenesis
Neuronal stem cells
TitleRecent Perspective About the Amyloid Cascade Hypothesis and Stem Cell-Based Therapy in the Treatment of Alzheimer's Disease
TypeBook chapter
Pagination144-174
Volume Number5
ESSN1875-8908
EISBN978-1-68108-231-8
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record